

**IN THE PATENT AND TRADEMARK OFFICE**

In The Matter of the Application of:

Serial No. : 88/350,376  
Mark : MAPS Public Benefit Corporation  
Applicant : MAPS PUBLIC BENEFIT CORPORATION  
Law Office : 108  
Examining Attorney: Lindsey H. Ben

Assistant Commissioner for Trademarks  
2900 Crystal Drive  
Arlington, VA 22202-3513

**DECLARATION OF RICK DOBLIN**

I, Rick Doblin, declare and state as follows:

1. This declaration is in support of MAPS Public Benefit Corporation’s (“MAPS PBC”) application for federal registration of MAPS PUBLIC BENEFIT CORPORATION, Serial Number 88/350,376, in response to the Office Action dated January 3, 2020. This declaration is based upon my personal knowledge.
2. I am the Chief Executive Officer of MAPS PBC, a Delaware public benefit corporation in good standing.
3. MAPS PBC is a Delaware Public Benefit Corporation that conducts FDA-compliant clinical research on MDMA, other psychedelics, and marijuana. MAPS PBC is a wholly-owned subsidiary of Multidisciplinary Association for Psychedelic Studies (“MAPS”), a 501(c)(3)-designated non-profit research and educational organization, founded in 1986.
4. MAPS, with and through MAPS PBC, completed the first FDA-compliant clinical trial of smoked botanical marijuana as a potential prescription medicine for specific medical uses in

January 2019. The study received full approval from the FDA, DEA, and relevant Institutional Review Boards (“IRB’s”). The study, titled, “Study of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD,” began in January 2017 at Scottsdale Research Institute, in Phoenix, Arizona, and completed its treatment phase in January 2019.

5. As the Founder and Executive Director of MAPS, and the CEO of MAPS PBC, I manage and direct the relationships that exist between MAPS as the sponsoring organization, MAPS PBC as the wholly-owned subsidiary corporation conducting and collaborating on the research, and the relevant regulatory agencies, including the HHS, FDA, NIDA, DEA, and relevant IRB’s.
6. I am personally familiar with each of the documents described below and attached to this declaration.
7. Attached as Exhibit A is true and correct copy of correspondence from Sarah Wattenberg, MSW, Senior Advisor for Substance Abuse Policy and Chairperson, Public Health Service Marijuana Research Review Committee, United States Government, to myself dated March 12, 2014, declaring United States Department of Health and Human Services clearance for purchase of research grade marijuana from the National Institute on Drug Abuse (“NIDA”) for the study titled “Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Five Different Potencies of Smoked or Vaporized Marijuana in 50 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD).”
8. Attached as Exhibit B is a true and correct copy of correspondence from Sarah Wattenberg to myself dated February 11, 2015, declaring United States Department of Health and Human Services clearance for purchase of research grade marijuana from the NIDA for the study, as amended, titled “Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot

Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD).”

9. Attached as Exhibit C is true and correct copy of the Schedule I Controlled Substance Registration Certificate for Researcher Suzanne Sisley, Primary Investigator in the study titled “Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD),” dated April 19, 2016.
10. Attached as Exhibit D is true and correct copy of correspondence from Nora D. Volkow, MD, Director of the National Institutes of Health National Institute on Drug Abuse, Department of Health and Human Services, United States Government, to myself and Rebecca Matthews dated June 3, 2015, authorizing United States Food and Drug Administration review of the NIDA Drug Master File for the study associated with Investigational New Drug (“IND”) # 110513 titled “Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)”
11. Attached as Exhibit E is true and correct copy of correspondence from Mitchell Mathis, Director, Division of Psychiatry Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research, Food and Drug Administration of the Department of Health and Human Services, United States Government, to myself dated September 2, 2015, concluding that the study associated with IND # 110513 was approved for initiation.

12. The FDA-approved study titled “Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD),” associated with IND # 110513 is a MAPS-Sponsored Clinical Trial conducted by MAPS PBC.

Pursuant to 28 U.S.C. § 1746, I, Rick Doblin declare under penalty of perjury that the foregoing is true and correct.

Executed on this 12th day of March 2020, in Philadelphia, Pennsylvania

A handwritten signature in cursive script that reads "Rick Doblin". The signature is written in black ink and is positioned above a horizontal line.

---

Rick Doblin